1 / 28

Viral Hemorrhagic Fevers

Viral Hemorrhagic Fevers. Michael Bell, MD Special Pathogens Branch Division of Viral & Rickettsial Diseases Centers for Disease Control and Prevention. VHF. Acute infection: fever, myalgia, malaise; progression to prostration Small vessel involvement:

tierra
Download Presentation

Viral Hemorrhagic Fevers

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Viral Hemorrhagic Fevers Michael Bell, MD Special Pathogens Branch Division of Viral & Rickettsial Diseases Centers for Disease Control and Prevention

  2. VHF • Acute infection: fever, myalgia, malaise; progression to prostration • Small vessel involvement: increased permeability, cellular damage • Multisystem compromise (varies with pathogen) • Hemorrhage may be small in volume (indicates small vessel involvement, thrombocytopenia) • Poor prognosis associated with: shock, encephalopathy, extensive hemorrhage

  3. Viral Hemorrhagic Fever viruses • Filoviruses Ebola Hemorrhagic fever (EHF) Marburg virus • Arenaviruses Lassa fever “New World Arenaviruses” • Bunyaviruses Rift Valley fever (RVF) Crimean Congo Hemorrhagic fever (CCHF)

  4. VHF: Viruses • Encapsulated, single stranded RNA viruses • Similar syndromes; different pathogenesis & treatment • Persistent in nature: rodents, bats, mosquitoes • Geographically restricted by host • Potential infectious hazards from laboratory aerosols

  5. Bunyaviruses • Crimean Congo hemorrhagic fever

  6. CRIMEAN CONGO HEMORRHAGIC FEVER(CCHF) • Extensive geographic distribution (Africa, Balkans, and western Asia) • Transmission: • Tick-borne (Hyalomma spp.) • Contact with animal blood or products • Person-to-person transmission by contact with infectious body fluids • Laboratory worker transmission documented • Mortality 15-40% • Therapy: Ribavirin

  7. Distribution of CCHF virus

  8. CCHF: Clinical features • 4-12 day incubation after tick exposure • 2-7day incubation after direct contact with infected fluids • Abrupt onset fever, chills, myalgia, severe headache • Malaise, GI symptoms, anorexia • Leukopenia, thrombocytopenia, hemoconcentration, proteinuria, elevated AST • Hemorrhages may be profuse (hematomas, ecchymoses)

  9. PREVENTION OF CCHF • DEET repellents for skin • Permethrin repellents for clothing – (0.5% permethrin should be applied to clothing ONLY) • Check for and remove ticks at least twice daily. • If a tick attaches, do not injure or rupture the tick. Remove ticks by grasping mouthparts at the skin surface using forceps and apply steady traction.

  10. CCHF: Pathogenesis • Viremia present throughout disease • IFA becomes positive in patients destined to survive days 4-6, often simultaneously with viremia • Recovery may be due to CMI or neutralizing antibodies • Patients that die usually still viremic • Virus grows in macrophages and other cells • DIC often present • Poor prognosis signaled by early elevated AST and clotting

  11. CCHF: Slaughterhouses • Sheep and cattle become viremic without disease • Blood and fresh tissues infective by contact • Possibility of establishing transmission of CCHF in holding pens by Hyalomma or other tick vectors

  12. Ribavirin • Guanosine nucleoside analog: blocks viral replication by inhibiting IMP dehydrogenase • Licensed for treatment of RSV and HCV • Potential adverse effects: • Dose dependent reversible anemia • Pancreatitis • Teratogen in rodents

  13. Ribavirin: indications • Filoviruses No • Rift Valley No… • CCHF Yes • Lassa Yes • Argentine HF Yes • Other New world Arena Maybe

  14. Ribavirin: toxicities • Teratogenic • Extravascular hemolysis • Bone marrow suppression • Rigors with abrupt iv administration • Reversible hyperbilirubinemia, hyperuricemia with oral administration • Pruritus, nausea, depression, cough

  15. Infection Control

  16. Laboratory safety: BSL-4 In contrast to patient-care, high-level protection required for: • Laboratory manipulation • Mechanical generation of aerosols • Concentrated infectious material • Viral culture

  17. VHF: Human-to-Human transmission • None: Yellow fever, Dengue, Rift Valley fever, Kyasanur, Omsk (arboviruses), hantaviruses • Low: Lassa and South American Arenaviruses • High: Ebola, Marburg, Crimean-Congo HF

  18. History of Infection Control Precautions • 1877 Separate facilities for infectious diseases • 1910 Antisepsis and disinfection • 1950-60 Closure of Infectious disease and TB hospitals • 1970 CDC:“Isolation Techniques for use in Hospitals” (7 categories, “over-isolation”)

  19. History of Infection Control Precautions • 1983 CDC Guideline: Isolation Precautions in Hospitals (Disease-specific + category-based including blood and body-fluids) • 1985 Universal precautions • 1987 Body substance isolation

  20. History of Infection Control Precautions • 1996 CDC/HICPAC revised guidelines: Standard Precautions

  21. Standard Precautions • Constant use of gloves and handwashing (plus face-shields, masks or gowns if splashes are anticipated) for any contact with blood, moist body substances, mucous membranes or non-intact skin.

  22. Standard Precautions • Constant use of gloves and handwashing (plus face-shields, masks or gowns if splashes are anticipated) for any contact with blood, moist body substances, mucous membranes or non-intact skin. • Additional, Transmission-based Precautions

  23. Standard Precautions Transmission-based Precautions • Airborne(TB, Chicken pox, Measles, Smallpox) • Droplet(Diphtheria, Pertussis, Meningococcus, Influenza, Mumps....) • Contact(Enteric infections, Respiratory infections, Skin infections, Conjunctivitis…. )

  24. VHF: Contact management • Casual contacts: e.g., shared airplane or hotel, No surveillance indicated • Close contacts:Direct contact with patient and/or body fluids during symptomatic illness. Fever watch during incubation period • High risk contacts:Needle stick, mucosal exposure to body fluids, sexual contact. Fever watch, consider inpatient observation.

  25. www.cdc.gov/ncidod/hip/isolat/isolat.htm Complete text of the current CDC/HICPAC Isolation Precautions are available on-line.

  26. www.cdc.gov/ncidod/dvrd/spb/index.htmwww.cdc.gov “viral hemorrhagic fevers”

More Related